Clinical investigations: statistical considerations

AI Summary

This regulatory guidance issued by the UK Medicines and Healthcare products Regulatory Agency (MHRA) outlines the comprehensive statistical requirements for manufacturers conducting clinical investigations. While the document is a general guidance rather than an inspection report for a specific company or date, it establishes the expected standards for data integrity across the industry. The guidance focuses on several critical phases of investigation, including the initial design, the conduct and monitoring phase, and the subsequent follow-up and reporting stages. A primary focus is placed on the statistical validity of safety data and the transparency of reporting issues identified during clinical trials. Under the UK's medical device regulatory framework, manufacturers are obligated to gather and present data that allows for a clear assessment of a device's performance and safety profile. To comply with these standards, manufacturers must implement robust monitoring systems and ensure that all safety-related findings are documented and analyzed using sound statistical principles. This proactive approach aims to mitigate risks associated with clinical data gaps and ensures that final reports provide a reliable basis for regulatory decisions regarding medical device approval and safety monitoring.